SCM
ENTA icon

Sigma Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Sigma Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-80,000
Closed -$1.83M – 191
2013
Q3 		$1.83M Buy
+80,000
New +$1.53M 0.08% 207

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
AP
AlpInvest Partners Amsterdam, Netherlands $49.7M AUM 23.93% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sigma Capital Management's ENTA Position: Q4 2013 in Review

Sigma Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2013, closing a stake of 80,000 shares — an estimated $1.83M sold.

Sigma Capital Management first reported a position in ENTA in Q3 2013 and held it in 1 quarter. The position peaked at $1.83M in Q3 2013. 66 funds tracked by Wall St. Rank hold ENTA as of Q4 2013.

  • Sigma Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Sigma Capital Management sold 80,000 Enanta Pharmaceuticals shares in Q4 2013, an estimated $1.83M.
  • Sigma Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Sigma Capital Management's Enanta Pharmaceuticals position peaked at $1.83M in Q3 2013.
  • 66 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2013.

Based on Sigma Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.